The invention essentially relates to oral dosage forms comprising a JAK3 inhibitor, preferably tasocitinib, suitable for modified release, and processes of preparing such oral dosage forms....
Cabazitaxel 890654-44-1 Bufexamac Bufexamac HDAC Inhibitors
没有评论:
发表评论